

Table S1 Clinical trials of CDK12 mutation in cancers

Trial number	Sponsor	Condition	Intervention	Phase	Period
NCT03318445	Pamela Munster	Solid Tumor, Unspecified, Adult	Drug: Rucaparib Drug: Irinotecan	1	2017-2020
NCT02952534	Clovis Oncology, Inc.	Metastatic Castration Resistant Prostate Cancer	Drug: Rucaparib	2	2017-2021
NCT03012321	Northwestern University	Prostate Cancer Metastatic Castration-Resistant Abnormal DNA Repair Metastatic Prostate Carcinoma Stage IV Prostate Cancer	Drug: Olaparib Drug: Abiraterone Acetate Drug: Prednisone	2	2017-2022
NCT03570619	University of Michigan Rogel Cancer center	Metastatic Castration Resistant Prostate Cancer Metastatic Cancer	Drug: Nivolumab Drug: Ipilimumab	2	2018-2021
NCT03842228	National Cancer Institute (NCI)	Advanced/metastatic/unresectable Malignant Solid Neoplasm	Drug: Copanlisib/ Hydrochloride Biological: Durvalumab Drug: Olaparib	1	2019-2021
NCT03786796	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer Metastatic	Drug: Olaparib	2	2019-2022
NCT04019964	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Prostate Cancer Recurrent Prostate Cancer	Drug: Nivolumab	2	2020-2025
NCT04030559	University of California, Davis	DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, Prostate Carcinoma,	Drug: Niraparib Drug: Niraparib Tosylate Monohydrate	2	2020-2025